Skip to main content

Advertisement

Table 2 Clinical and laboratory data of patients with liver cirrhosis and hepatocellular carcinoma

From: Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography–mass spectrometry

Characteristics LC HCC P
AFP (ng/mL) 6.2 ± 15.8 507.8 ± 1565.9 < 0.001*
AFP ≥ 20 ng/mL 2 (6.67) 12 (37.5) -
AFP ≥ 200 ng/mL 0 (0.0) 6 (18.8) -
ALT (UI/mL) 35.4 ± 41.3 39.5 ± 43.2 0.698
AST (UI/mL) 37.3 ± 22.4 45.3 ± 43.0 0.746
ALP (U/L) 86.6 ± 51.6 119.2 ± 70.1 0.022*
GGT (U/L) 64.2 ± 98.2 108.1 ± 121.0 0.045*
Total bilirubin (mg/dL) 0.7 ± 0.3 1.1 ± 1.4 0.481
Albumin (g/dL) 4.7 ± 0.4 4.4 ± 0.8 0.117
Platelets (*1,000/mm3) 155.8 ± 89.5 156.0 ± 86.3 0.910
PT (seconds) 14.1 ± 2.1 13.2 ± 1.7 0.013*
Child-Pugh score    
 A 30 (53.6) 26 (46.4) 0.030*
 B or C 0 (0.0) 6 (100.0)
Total cholesterol (mg/dL) 179.4 ± 38.1 172.8 ± 41.0 0.511
Tumor size (mm) - 37.0 ± 23.0 -
BCLC stage    
 0 - 5 (15.6) -
 A - 14 (43.8) -
 B - 10 (31.2) -
 C - 1 (3.1) -
 D - 2 (6.3) -
  1. Results are presented as number and percentage for categorical variables and as mean value and standard deviation for continuous variables. LC liver cirrhosis, HCC hepatocellular carcinoma, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma glutamyl transpeptidase, PT prothrombin time, BCLC Barcelona-Clinic Liver Cancer. *Significant at 0.05